Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic reviewCase Report Published on 2024-01-082024-09-05 Journal: BMC Geriatrics [Category] update2024, [키워드] hemophagocytic lymphohistiocytosis Immune-related adverse event Pembrolizumab [DOI] 10.1186/s12877-023-04625-3 PMC 바로가기 [Article Type] Case Report
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsarticle Published on 2023-02-082024-09-05 Journal: Hepatology international [Category] update2024, [키워드] adverse events Hepatitis B virus Hepatocellular carcinoma lenvatinib nivolumab PD-1 inhibitor Pembrolizumab Un-resectable [DOI] 10.1007/s12072-022-10480-y PMC 바로가기 [Article Type] article
Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapyCase Series Published on 2022-11-242024-09-04 Journal: JAAD Case Reports [Category] 대상포진, [키워드] drug eruption fixed drug eruption Immunotherapy lichen sclerosus nivolumab NSCLC, non-small-cell lung cancer PD-1 inhibitor PD1, programmed cell death protein 1 Pembrolizumab post-herpetic isotopic response pseudolymphoma Rash scleredema skin Toxicity [DOI] 10.1016/j.jdcr.2022.11.020 PMC 바로가기 [Article Type] Case Series
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II studyClinical Trial Published on 2022-10-012022-10-05 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] addition antibody Cell cellular Combination COVID-19 deaths discharge Efficacy and safety elevated faster Hospitalization hospitalized patient hyperinflammation immune dysregulation Infection interleukin 6 receptor lymphocyte males mechanical ventilation median age median time objective Open-label Patient Pembrolizumab Pneumonia Randomized reduced Result SARS-COV-2 infection severe SARS-CoV-2 Standard of care TCZ Tocilizumab Trial with COVID-19 [DOI] 10.1016/j.ijid.2022.08.007 [Article Type] Clinical Trial
Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 PandemicCOVID-19 팬데믹 기간 동안 비소세포폐암에서 면역관문억제제에 대한 연장된 간격 투여의 안전성 및 효능Article Published on 2022-03-012022-09-12 Journal: Clinical lung cancer [Category] MERS, SARS, 진단, [키워드] adverse event Cell Characteristics Checkpoint blockade clinically Cohort comparable consolidation coronavirus COVID-19 COVID-19 pandemic Dose adaptation dose reduction Dosing effective Efficacy Extended Frequency immune Immunotherapy in both groups inhibitor initiated interval lung cancer nivolumab no difference occurred Occurrence Patient Pembrolizumab receiving reduced reduction in resulting Retrospective analysis Safe Safety stage III Standard dose survival therapy Toxicity Treatment were assessed [DOI] 10.1016/j.cllc.2021.12.005 PMC 바로가기 [Article Type] Article
Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19증례 보고: 코로나19 증상이 있는 동안 면역 체크포인트 억제를 새로 받은 전이성 비소세포폐암 환자의 임상 관리Case Reports Published on 2021-12-202022-09-12 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] activated ambulatory patient Analysis anti-cancer treatment anti-PD1 antiviral immunity blockade CD4 CD8 cellular change clinical Corticosteroid Course COVID-19 CT scan Effect feasible Follow-up healthy High-dose Hospitalized humoral immune response IgG immune checkpoint Immunotherapy inhibition initiated lesion lung cancer male malignancy management metastatic Neutralizing NSCLC Patient PD1 Pembrolizumab Pneumonia Pneumonitis presenting Radiographic SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection serum sustained symptomatic T cell Tfh the patient treatment initiation worsened [DOI] 10.3389/fimmu.2021.798276 PMC 바로가기 [Article Type] Case Reports
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patientsClinical Trials Published on 2021-12-082024-09-04 Journal: Cancer [Category] 대상포진, [키워드] Asia Chemotherapy Gastric cancer gastroesophageal junction cancer Pembrolizumab programmed death 1 [DOI] 10.1002/cncr.34019 PMC 바로가기 [Article Type] Clinical Trials
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas림프종의 분리 된 경우에서 SARS-COV-2에 의한 희귀 항 종양 면역 반응의 잠재적 분자 메커니즘Article Published on 2021-09-252022-09-01 Journal: Viruses [Category] SARS, 유전자 메커니즘, 진단, [키워드] anti-tumor immune response anti-tumor immunotherapy Apoptosis approach B-cell binding binding site Cancer CD27 CD45 cell proliferation classical Complete Complete Remission complex component domain Extracellular follicular Follicular lymphoma gamma-tubulin ring complex Hodgkin lymphoma induce inhibit initial interact interacting residues internalization Isolated lymphoma lymphoproliferative disorders M pro M protein membrane microtubule molecular mechanism monoclonal antibodies monoclonal antibody motif NF-kB nivolumab nsp10 Nsp7 oncogenesis ORF3a ORF3a protein PD-1 Pembrolizumab Potential Protein Proteins receptor Remission reported response responsible SARS-CoV-2 SARS-COV-2 infection Signaling the SARS-CoV-2 therapeutic potential TRADD TUBG1 virus [DOI] 10.3390/v13101927 PMC 바로가기 [Article Type] Article
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemicResearch article Published on 2021-09-012022-10-05 Journal: Clinical and Translational Radiation Oncology [Category] 치료법, [키워드] Cancer cancer patient change changed Chemotherapy Chemotherapy treatment clinical conducted Consensus COVID-19 pandemic dose Feeding tube First wave group Guidance head head and neck cancers Histopathology Immunotherapy initiated introduced majority management Modification Neck NHS offered oncology oncology patient pandemic Patient patients Pembrolizumab questionnaire Radiotherapy required Result reveal SARS-CoV-2 selective standard treatment surgical survey Treatment Treatment modifications Variation [DOI] 10.1016/j.ctro.2021.06.002 [Article Type] Research article
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 AntibodyArticle Published on 2021-08-242023-06-03 Journal: Frontiers in Immunology [Category] B형 간염, Fulltext, [키워드] atezolizumab HCC Immunotherapy PD-1 PD-L1 Pembrolizumab [DOI] 10.3389/fimmu.2021.712351 PMC 바로가기